Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03UBW
|
|||
| Former ID |
DNCL002252
|
|||
| Drug Name |
Ficlatuzumab
|
|||
| Synonyms |
AV-299
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Phase 2 | [1] | |
| Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 2 | [1] | ||
| Pancreatic cancer [ICD-11: 2C10] | Phase 2 | [2] | ||
| Squamous cell carcinoma [ICD-11: 2B60-2D01] | Phase 2 | [2] | ||
| Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [2], [3] | ||
| Company |
AVEO Pharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02318368) A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.